Résumé
This thesis examines the evolution of therapeutic cannabis (Cannabis sativa) indications over time, based on data from European and global databases such as EudraCT and ClinicalTrials.gov. Research shows a significant increase in clinical trials aimed at evaluating the efficacy of cannabis for various medical conditions. In neurology, cannabis, particularly cannabidiol (CBD), has shown promising results in managing Lennox-Gastaut and Dravet syndromes, as well as multiple sclerosis. Studies reveal that CBD can reduce the frequency and severity of epileptic seizures, offering a new therapeutic option for patients resistant to conventional treatments. In oncology, clinical trials have explored the use of Sativex® for pain management in patients with advanced cancer. While preliminary results are promising, further research is needed to validate these benefits. In psychiatry, studies on therapeutic cannabis have yielded mixed results. Some research indicates potential benefits, particularly for trichotillomania and neuropsychiatric symptoms related to dementia, but other studies have not met their primary endpoints, highlighting the need for continued investigation. Regulatory frameworks in Germany, Israel, and Canada have facilitated rigorous clinical research and patient access to medical cannabis. This thesis concludes that, although therapeutic cannabis shows notable potential, it is crucial to continue research to refine dosages, formulations, and appropriate indications, while ensuring the safety of treatments.